Wei is Erasca’s Chief Medical Officer, bringing over a decade of experience in clinical development across early- and late-stage clinical trials. He joined Erasca from Nektar Therapeutics, where he was senior vice president and head of development as well as a member of the executive committee. He was responsible for all development functions and the clinical development of Nektar’s pipeline, including advancing bempegaldesleukin into multiple registrational trials and achieving FDA breakthrough therapy designation in metastatic melanoma. Prior to Nektar, Wei held roles of increasing responsibility at Roche/Genentech, most recently as the global development lead in cancer immunotherapy for lung cancer and head and neck cancer. Under his leadership, his team oversaw 10 registrational studies, completed five positive Phase III trials, and achieved three US and EU regulatory approvals for Tecentriq®, including the first advancement in first-line small cell lung cancer in three decades. He was also the site head for oncology product development for Roche China, where his team achieved multiple additional regulatory approvals for Avastin®, Zelboraf® and Tarceva®. He is a past recipient of the ASCO Young Investigator Award and the AACR-AstraZeneca Translational Lung Cancer Award. He was on faculty at MD Anderson Cancer Center, where he completed his medical oncology fellowship.
He completed his internal medicine residency at Massachusetts General Hospital and received his M.D. from Harvard Medical School and his B.A. in physics from Haverford College.